4 5 0 5 9

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊










更多详情 >>



停止接受任何荟萃分析文章 (Meta-analysis)

请注意:我们所有期刊已于 2019 年 4 月 1 日停止接受任何荟萃分析 (Meta-analysis)文章的提交。


会员计划

我们很高兴为机构提供一种切实的方法以支持开放获取并鼓励教师和研究人员通过开放获取模式尽可能广泛地传播他们的作品。

更多详情 >>

 

公司动态

德孚医药出版社最新文章精选 (Part 3)

 

德孚医药出版社专门从事开放获取同行评议期刊的出版业务,这些期刊广泛地涉及科学、技术特别是医药领域。德孚旗下共有 130 多种开放获取期刊,许多优秀医药论文已经在我们的中文网站上发表。我们特意摘选了一些论文,与大家一起分享:


共轭的树枝状聚合物及超声波介导的透皮双氯芬酸药物输送系统

The purpose of the present study was to develop a novel transdermal drug-delivery system comprising a polyamidoamine dendrimer coupled with sonophoresis to enhance the permeation of diclofenac (DF) through the skin. The novel transdermal drug-delivery system was developed by using a statistical Plackett–Burman design.

Hairless male Wistar rat skin was used for the DF-permeation study. Coupling media concentration, ultrasound-application time, duty cycle, distance from probe to skin, and a third-generation polyamidoamine-dendrimer concentration were selected as independent variables, while in vitro drug release was selected as a dependent variable. Independent variables were found to be statistically significant (<0.05).

DF gel without dendrimer and ultrasound treatment to skin (passive delivery, run 13) showed 56.69 µg/cm
2 cumulative drug permeated through the skin, while the DF-dendrimer gel without sonophoresis treatment (run 14) showed 257.3 µg/cm2 cumulative drug permeated through the skin after 24 hours. However, when the same gel was applied to sonophoresis-treated skin, drastic permeation enhancement was observed.

In the case of run 3, the cumulative drug that permeated through the skin was 935.21 µg/cm
2. It was concluded that dendrimer-coupled sonophoresis-mediated transdermal drug delivery system has the potential to enhance the permeation of DF through the skin.



CD20 纳米抗体梳的构建及其抗淋巴瘤作用研究


利妥昔单抗(Rituximab, RTX)是一种针对人CD20 抗原的人-鼠嵌合型单克隆抗体,其出现大大提高了淋巴瘤的治疗效果。然而,并非所有的患者对利妥昔单抗的治疗都有较好的反应,且随着治疗的深入,越来越多的患者逐步表现出对其治疗的耐药,这大大限制了利妥昔单抗的临床应用。

目前的研究表明,利妥昔单抗主要通过以下四种机制来杀伤肿瘤细胞——补体依赖的细胞毒作用(CDC), 抗体依赖的细胞介导的细胞毒作用(ADCC),Caspase 依赖的凋亡以及溶酶体介导的程序性死亡(PCD)。然而,迄今为止尚没有一种靶向 CD20 的单克隆抗体或者抗体衍生物能够同时激活这四种机制。本研究应用纳米医学技术,将两种不同类型的 CD20 抗体(型抗体利妥昔单抗,II 型抗体托西莫单抗)用聚乙烯亚胺(PEI)载体进行交联,成功制备出一种新型的针对人CD20 抗原的纳米抗体梳 PPRT

与游离的单克隆抗体相比,PPRT 纳米抗体梳对淋巴瘤细胞表面 CD20 抗原拥有相当的结合能力和更低的解离能力。随后的研究结果表明,该纳米抗体梳能够通过“细胞内交联”和“跨细胞交联”同时激活上述与 CD20 
抗体相关的杀伤肿瘤细胞的所有四条通路。体内研究结果表明,PPRT 纳米抗体梳具有比游离 CD20 抗体更慢的清除率和更长的半衰期,在体内外研究中显示出极强的淋巴瘤杀伤效果。